5-Amino-1MQ research and evidence overview

The entire published case for 5-Amino-1MQ rests on mouse and cell-culture work with a class of small molecules called NNMT inhibitors. Not one controlled human trial of 5-Amino-1MQ has been published or, as of this writing, registered to a completed result. The rodent findings are real, specific, and reasonably well replicated within one research group — but the gap between "reduces fat mass in mice fed a high-fat diet" and "does anything measurable in a person" is the whole question, and nobody has answered it.

Nicotinamide N-methyltransferase (NNMT) consumes two things cells need: nicotinamide, a precursor for NAD+, and S-adenosylmethionine (SAM), the main methyl donor. NNMT is heavily expressed in the fat tissue of obese animals, which is what made blocking it interesting. 5-Amino-1MQ belongs to the methylquinolinium chemical class developed for exactly this purpose — small, membrane-permeable molecules that fit the NNMT active site.

The study most often cited for 5-Amino-1MQ is a 2018 paper in Biochemical Pharmacology from a University of Texas group (Neelakantan et al., PMID 29155147). It reported that methylquinolinium analogues with primary-amine substitutions — the chemical family 5-Amino-1MQ sits in — crossed membranes well, did not inhibit related methyltransferases or NAD+ salvage enzymes, and in cultured adipocytes lowered the NNMT reaction product 1-methylnicotinamide while raising intracellular NAD+ and SAM and suppressing lipogenesis.

In diet-induced obese mice, a potent inhibitor from the series significantly reduced body weight, white adipose mass, adipocyte size, and plasma total cholesterol, with no change in total food intake and no observable adverse effects. That last detail matters: the weight change was not a byproduct of the animals eating less.

Two honest caveats. First, this is a target-validation paper — its stated purpose was to establish NNMT as a viable drug target, not to characterise one marketed compound. Second, mice on a high-fat diet are a forgiving model; plenty of compounds that reverse obesity in that setting have gone nowhere in humans.

A later study from an overlapping group extended NNMT inhibition to sarcopenia (Dimet-Wiley et al., Scientific Reports 2024, PMID 38969654). Mice aged 22 to 24 months received an NNMT inhibitor, intensive exercise, or both. Sedentary treated mice showed roughly 40% greater grip strength than sedentary controls, while exercise alone produced about 20%; the combination reached roughly 60%. Intramyocellular lipid content improved, and combined treatment plus exercise increased gastrocnemius fibre cross-sectional area.

Note the authorship: several authors are affiliated with the company developing NNMT inhibitors. That does not make the result wrong, but it is the kind of disclosure worth registering when a finding is this favourable and this unreplicated outside the originating network.

Everything downstream of animals. There is no published human pharmacokinetic study of 5-Amino-1MQ, no dose-ranging data in people, no controlled trial of body composition or strength, and no long-term safety record. NNMT is expressed in the liver and other tissues, so chronic systemic inhibition raises questions the rodent studies were not designed to answer.

A further practical problem: material sold as 5-Amino-1MQ is not the pharmaceutical-grade compound used in these papers, and purity, dose accuracy, and identity are not independently verified. Claims that translate a mouse grip-strength number into a promised human outcome are not supported by anything in the literature above.